Investigative report on Chinese pertuzumab markets, 2016-2020 and 2021-2025: the first monoclonal antibody called “HER dimerization inhibitor”, mainly used to treat HER2-positive breast cancer


DUBLIN, March 07, 2022–(BUSINESS WIRE)–The “China Pertuzumab Market Investigation Report 2021-2025” report has been added to from offer.

Pertuzumab is the first monoclonal antibody called “HER dimerization inhibitor”. It is mainly used to treat HER2-positive breast cancer. It was developed by Genentech, a subsidiary of Roche Pharma (Schweiz) AG, and was first approved in 2012. Pertuzumab entered the Chinese market in 2019. As of the first half of 2021, Roche Pharma (Schweiz) AG is the only manufacturer in the Chinese market of pertuzumab.

According to the market research, since Pertuzumab entered the Chinese market, sales have increased rapidly from CNY 21.15 million in 2019 to CNY 501.69 million in 2020. The annual sales growth rate of Pertuzumab is 2272.15%.

The analyst expects that, based on pertuzumab’s price reduction, its sales volume will continue to grow from 2021 to 2025. Pertuzumab was included in the health insurance reimbursement catalog at the beginning of 2020, and the price of each 0.42g dose has been reduced by CNY18. ,800 to 4955 CNY.

This price is valid until the end of 2021. The price of pertuzumab is expected to drop further in the future. The price reduction will reduce the burden on patients, thereby increasing pertuzumab’s utilization rate and sales. At the same time, the huge patient population will also allow the pertuzumab market to continue to grow. Breast cancer is one of the top ten new cancer cases in China in 2020, reaching 420,000.

Among them, HER2 positive patients accounted for 20-30%. A large number of patients also increased the demand for pertuzumab. In addition, the efficacy of the combination therapy of pertuzumab and trastuzumab has also established its market potential.

Topics Covered:

  • The impact of COVID-19 on the Chinese pertuzumab market

  • Pertuzumab sales value in China 2016-2020

  • Competitive landscape of Chinese pertuzumab market

  • pertuzumab price in china

  • Pertuzumab Price in China by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese pertuzumab market

  • China pertuzumab market outlook from 2021 to 2025

Main topics covered:

1 Pertuzumab relevant concepts

1.1 Indications for pertuzumab

1.2 Pertuzumab Development in China

1.3 Government approval of pertuzumab in China

1.4 The impact of COVID-19 on pertuzumab sales in China

2 China Pertuzumab Sales, 2019-2020

2.1 Pertuzumab Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Region

2.2 Pertuzumab Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Pertuzumab Sales by Dosage Form in China, 2019-2020

2.3.1 Injection

2.3.2 Analysis of other dosage forms

3 Pertuzumab Key Manufacturers Analysis in China, 2019-2020

3.1 Pertuzumab Key Manufacturers Market Share Analysis

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 Roche Pharma (Switzerland) AG

3.2.1 Company profile

3.2.2 PERJETA (Pertuzumab by Roche Pharma (Schweiz) AG) Sales in China

4 pertuzumab price for different manufacturers in China, 2020-2021

4.1 Roche Pharma (Switzerland) Ltd (PERJETA)

4.2 Analysis of other companies

5 China Pertuzumab Drug Market Outlook, 2021-2025

5.1 Influencing Factors of China Pertuzumab Market Development

5.1.1 The impact of COVID-19 on the Chinese pertuzumab market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

List of graphics

Chart Patent Information for Pertuzumab Injection Registration in China

Chart Global Pertuzumab Injection Sales Value

Chart China Pertuzumab Injection Sales Value, 2019-2020

Chart China Pertuzumab Injection Sales Value by Region, 2019-2020

Chart China Pertuzumab Injection Sales Volume, 2019-2020

Chart China Pertuzumab Injection Sales Volume by Region, 2019-2020

Chart Pertuzumab Top Manufacturers Sales Market Share by Value in China, 2019-2020

Chart China PERJETA Sales Value and Volume, 2019-2020

Chart China PERJETA Benchmark Price, 2020-2021

Chart China Pertuzumab Sales Value Forecast, 2021-2025

Chart China Pertuzumab Sales Volume Forecast, 2021-2025

For more information on this report, visit

See the source version on

Laura Wood, Senior Press Officer
[email protected]

For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900


Comments are closed.